Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

New NIH funding to Burd lab!

January 19, 2022

New NIH funding to Burd lab!

Craig Burd

Many congratulations to Craig Burd, whose R01 entitled "Estrogen receptor beta is a targetable melanoma tumor suppressor" was recently funded for five years! Building on observations that melanoma is more common in men than in women, and that decreased levels of estrogen receptor beta (ERβ) are correlated with disease progression, Dr. Burd and his team propose that signaling through ERβ regulates melanocyte biology, impacts immune recognition of the melanoma tumors, and that estrogen signaling protects against melanoma.  These studies will also As an integral part of  evaluate the potential of ERβ-specific agonists in enhancing current melanoma therapies.

Congratulations to Dr. Burd and his lab!